TERESA RAMERTH: Open Payments
NPI 1902110315 · FRONT ROYAL, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$801 in 38 payments from 10 companies in 2025. Trend: 2023 $788 · 2024 $1,176 · 2025 $801
Food & beverage: $801
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $462 |
| Otsuka America Pharmaceutical, Inc. | 3 | $103 |
| ABBVIE INC. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Janssen Pharmaceuticals, Inc | 1 | $26 |
| Abbott Laboratories | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| BETA BIONICS, INC. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
Products named: CAPLYTA, REXULTI, VRAYLAR, HETLIOZ, SPRAVATO, FANAPT, FREESTYLE LIBRE 3, MOUNJARO.
Industry payments across VA — which companies pay providers there.
